Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

pharmaceutical medicine > clinical drug development > Flashcards

clinical drug development Flashcards

1
Q

GLP

A

good labratory practice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ICH

A

international conference on Harmonization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

NME

A

new molecular entities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

FIH or FIM

A

FIRST IN HUMAN/MAN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

SAD

A

Single Ascending dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ATD

A

anticipated therapeutic dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

MAD

A

multiple ascending dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

IMP

A

investigational medicinal product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

CTA

A

clinical trial application

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CIB

A

clinical investigator brochure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ICF

A

informed consent form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Belgium competent authorities

A

department of Research and devlopment of the federal agency for medicine and health product FAMHP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IND

A

investigational new drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IB

A

investigator brochure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MRSD

A

maximal recommended starting dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MABEL

A

minimal anticipated biological effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

HED

A

human equivalent dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PAD

A

pharmacologically active dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

pivotal trial

A

phase 2 also called like that because it represents the most rigorous demonstration of a medicine efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MED

A

minimal effective dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Phase 3 clinical trial

A

is a trial conducted in the patient population for which the medicine is intended, after efficacy has been demonstrated and generating additional data on efficacy and safety in relatively large number of patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

NDA

A

new drug application

23
Q

Superiority trial

A

during phase 3, is done to detect difference between treatment they want to prove that the new treatment is better Thant the existing one. One sided analysis cause you just prove that drug A is better than B

24
Q

Equivalence trial

A

phase 3 and is done to confirm the absence of difference. It is more popular at the moment
you show that drug A is as good as drug B no difference no better no worse. Statistically it is really complex cause it is a two side kind go testing statistically so not popular anymore

25
Q

non inferiority trial

A

phase 3 and you show that the new treatment is at least as effective as. It should not be worse, it might even be better but you don’t check that. One sided testing then and easier to rpove

26
Q

non inferiority trial

A

phase 3 and you show that the new treatment is at least as effective as. It should not be worse, it might even be better but you don’t check that. One sided testing then and easier to rpove

27
Q

Bonafide phase 4 stsudies

A

investigate the effectiveness of drug in real life and the safety too in the context of pharmacovigilance. I trie to get the best real possible complete picture of benefit and risk of the drug

27
Q

seeding trial

A

a pseudo clinical trial designed by the company that is put in place to promote the use of a product that was recently approved. They try too appear like they want to answer a scientific question but it is really more of a marketing strategy to get the physician to prescribe the drug

28
Q

hard endpoints

A

objective and measurable endpoint such as death or survival or decreased morbidity

29
Q

surrogate endpoints

A

they are parameters more something that have to be measured such as a biomarker. Something related to a clinical endpoint with a sort of predictive parameter that can replace the clinical endpoints

when you try to show your drug is better than the existing one, ou take surrogate endpoint to how it. Advantage too cause it is quicker to get these information than morbidity

30
Q

clinical endpoints

A

describe how patient feel function survive such as quality of life survival morbidity mortality etc. depending upon what you think the most important are for this drug, you can refer to certain endpoints as being primary or secondary

31
Q

SoC

A

standard of care

32
Q

RCT

A

randomized controlled trial

it is prospective and analytical and experimental studies
it is the most convincing one

advantages is that they can be controlled for the unknown and unmeasurable cofounder, very powerful in terms of statistics. however you a some limitation such as the number of participant, the exposure and the follow up

there are some inclusion nd exclusion criteria (limit external validity) artificial expensive ethical etc so don’t forget these

33
Q

IVRS

A

Interactive voice response system

34
Q

nocebo

A

negative expectation resulting in undesirable effect

35
Q

therapeutic advantage

A

difference of effect between the real compound and placebo

36
Q

ECTA

A

EXPLORATory clinical trial application

part of the early development before/part of phase 1
limited non-clinical toxicology so very limited human exposure
no therapeutic intend
no intention to loof at MTD

MRSDA divided by 50

allow earlier differentiation of promising compounds
expose human earlier
reduced cost of closed medicine
fewer studies and animals

microdosing 500 ug less

you can use it to look at the biodistribution and receptor occupancy using PET
PK grounds carbon 14 plasma concentration

tissue distribution and R occupancy

37
Q

umbrella/platform trial

A

one disease but we look for different possible therapy (breast cancer or covid)

38
Q

basket/bucket trails

A

here it is one therapy that is tested in different disease (cancer too). Eg tissue/tumor agnostic treatment
so they ignore the type of tissue where the tumor is occurring and just focus on the type of mutation.

39
Q

adaptive design

A

umbrella and kucket approach together.

you think about all the different combination possible and therefore taste more combination more efficiently and quicker

40
Q

PoP studies

A

proof of principle

41
Q

DART

A

developmental and reproductive toxicity

42
Q

parallel group design

A

is randomization of people in two groups that are given another treatment for the whole duration of the trial

the advantages are that this can be long lasting, easy to perform and anlyse

however, you introduce a large variability because the two groups are technically not identical so you really need a big number of participant to get over this.

43
Q

cross over design

A

you divide in two groups and give them a certain treatment. After x amount of time you stop the treatment, allow for a washout time and exchange the treatment or no treatment between the group. This reduces the number of participants and variability, as every subject has its own control.

However, there are different problem such as the period effect of disease which is when the disease itself is not sufficiently stable and does not allow to perform a cross over design

some subject could die during the first part, so you need people that will be ok over the two parts of the treatment

you also have the carry over effect of R - it is when participant in the first group that get the drug get better or cured you cannot really switch them to the other treatment

the washout period can also be very comp^licated (for example not done with AB) as people need to get back to the baseline

very complicated analyse

44
Q

eIND

A

exploratory investigational new drug

45
Q

Master protocol

A

are a last alternative approach to increase the efficiency of drug development

at the beginning, it was really one treatment one disease one protocol. The new approach tries to maximise the number of questions answered in a shorter time

they design overarching protocol to answer multiples question at the same time such as for precision medicine, in antibiotic research or oncology

it can be really complicated and expensive to make a new protocol every time for each different mutation responsible for a certain type of breast cancer so we try to bring everything in one protocol

it includes the umbrella/platform trial, the basket. bucket trial and adaptive design

the advantages are that it uses a common screening platform
there is 1 overlooking organisation, it uses a network of experiences clinical centres, you can use the same controls group

however it does cost a lot of time and money, it requires a complex organisation and the start up time can be long

46
Q

Case report

A

it is about 1 signle case/observation that is unusual and rare. You can then challenge dechallenge rechallenge to observe the relationship between exposure and consequence

advantages is that is it cheap and hypothesis generating, as well as easy

however it give little evidence on causalityn you can’t test these hypothesis

pbservational and descriptive

47
Q

case serie

A

when you are pooling diffferent cases reports with a comparable history - you try to get a description of a characteristic and outcome among a group:

its great as it can estimate the number of incidences (rule of three) and hypothesis generating.

However you again have little evidence on causality, you have no control population to compare with and no hypothesis testing

it is again observational and descriptive

48
Q

case control

A

observational and analytical

you compare cases with control and you look at the differences in preceding exposure - so retrospective

you know who has the disease and who not and you look at how is the exposure different

you then have the risk in odds ratio

adv are that you can investigate rare and lates response, can check for multiple exposure at the tiam and is easy quick cheap

however it is sensitive to bias in terms of selection, information, recall and you also can get some confounding effect

49
Q

cohort studies

A

are observational and analytical. However, this one involves a cohort that will be followed over time from exposure to a consequence. it can be prospective, follow up over time

it can be retrospective and ambidirectional too.

adv is that multiple responses can be investigated like smoking can give COPD/Lung cancer,
you can check for rare exposure and
you get information on incidence
selection bias is less likely

neg is that you need a very large group, it is also sensitive to bias on outcome data and it is very long experiment

50
Q

MRSD advantage and inconvenitent

A

it is simple to use and has historical evidence based
however the approach is typically done on small molecule such as NCE
ignore step 5 and too simple allomertric calling

51
Q

MED

A

minimal effective dose

52
Q

biomarker

A

also allows to predict PD

does the binding predict a good response

pharmaceutical medicine (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions